Role of Infectious Diseases in the Antiphospholipid Syn

Current Rheumatology Reports 20, 62 DOI: 10.1007/s11926-018-0773-x

Citation Report

#	Article	IF	CITATIONS
1	Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 460.	4.8	21
2	Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. Clinical Rheumatology, 2020, 39, 1347-1355.	2.2	12
3	Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. Clinical Infectious Diseases, 2021, 73, e2869-e2874.	5.8	69
4	Acute aortic thrombosis in COVID-19. Journal of Vascular Surgery Cases and Innovative Techniques, 2020, 6, 483-486.	0.6	25
5	D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review. ERJ Open Research, 2020, 6, 00260-2020.	2.6	86
6	Coagulopathy in COVID-19: Focus on vascular thrombotic events. Journal of Molecular and Cellular Cardiology, 2020, 146, 32-40.	1.9	49
7	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?. Drugs, 2020, 80, 1383-1396.	10.9	93
8	Head, Neck, and Abdominopelvic Septic Thrombophlebitis: Current Evidence and Challenges in Diagnosis and Treatment. Hamostaseologie, 2020, 40, 301-310.	1.9	28
9	Deep Vein Thrombosis and Pulmonary Embolism in the Setting of Mycoplasma Infection. Case Reports in Medicine, 2020, 2020, 1-3.	0.7	1
10	Splenic infarction and infectious diseases in Korea. BMC Infectious Diseases, 2020, 20, 915.	2.9	8
11	Antiphospholipid Antibodies in Critically III Patients With COVIDâ€19. Arthritis and Rheumatology, 2020, 72, 1998-2004.	5.6	135
12	Dorsolateral medullary infarction during skin infection by Stenotrophomonas maltophilia in a patient with triple antiphospholipid antibody positivity: a case-based review. Clinical Rheumatology, 2021, 40, 2965-2971.	2.2	2
13	Presence of antiphospholipid antibodies in COVID-19: a case series study. Annals of the Rheumatic Diseases, 2021, 80, e73-e73.	0.9	60
14	Venous thrombosis in a systemic lupus erythematosus patient with antiphospholipid antibodies coinciding with mild Covid-19. Lupus, 2021, 30, 172-174.	1.6	7
15	Should COVID-19 be branded to viral thrombotic fever?. Memorias Do Instituto Oswaldo Cruz, 2021, 116, e200552.	1.6	5
16	Anticardiolipin Antibodies in COVID-19 – Report of Three Cases. Medicina Interna (Bucharest, Romania:) Tj ETQ	q110.784	4314 rgBT
17	Potential mechanisms of cerebrovascular diseases in COVID-19 patients. Journal of NeuroVirology, 2021, 27, 35-51.	2.1	24
18	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. Journal of Microbiology, Immunology and Infection, 2021, 54, 37-45.	3.1	5

ARTICLE IF CITATIONS # Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search 20 1.4 15 of a better approach. Journal of Thoracic Disease, 2021, 13, 1239-1255. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologiya, 2021, 1.0 28 59, 5-30. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative 22 0.9 39 patients. Annals of the Rheumatic Diseases, 2021, 80, 1236-1240. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nature 594 Reviews Immunology, 2021, 21, 319-329. Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. 24 3.0 23 Mayo Clinic Proceedings, 2021, 96, 989-1005. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmunity Reviews, 2021, 20, 102798. 5.8 Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. 26 2.7 31 Seminars in Thrombosis and Hemostasis, 2022, 48, 055-071. The contact system in liver injury. Seminars in Immunopathology, 2021, 43, 507-517. 6.1 COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?. Seminars in Thrombosis and 28 2.7 44 Hemostasis, 2022, 48, 072-092. The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year 29 3.2 Prospective Study. Biomedicines, 2021, 9, 901. Frenemies within: An Endocarditis Case in Behçet's Disease. Journal of Personalized Medicine, 2021, 11, 30 2.5 2 728. Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor. 3.2 Biomedicines, 2021, 9, 899. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that 32 7.2 36 breaks the camel's back?. Cytokine and Growth Factor Reviews, 2021, 60, 52-60. Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations). Śovremennaya Revmatologiya, 2021, 15, 87-93. COVID-19 coagulopathy and antiphospholipid syndrome. Revista Colombiana De ReumatologÃa, 2022, 29, 34 0.1 1 S25-S34. Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. Frontiers in Immunology, 2021, 12, 726820. Cutaneous Pathology of COVID-19 as a Window into Immunologic Mechanisms of Disease. 37 1.7 6 Dermatologic Clinics, 2021, 39, 533-543. Antiphospholipid antibody syndrome and dengue fever. Medical Journal of Dr D Y Patil Vidyapeeth, 38 0.1 2021,.

CITATION REPORT

CITATION REPORT

ARTICLE IF CITATIONS # The role of infections in SLE pathogenesis. , 2021, , 257-270. 0 39 Autoimmunity as the comet tail of COVID-19 pandemic. World Journal of Clinical Cases, 2020, 8, 0.8 3621-3644. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: 44 Diagnostic and therapeutic perspectives (Review). International Journal of Molecular Medicine, 2020, 4.0 73 46, 903-912. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 353-367 Catastrophic Antiphospholid Syndrome – An Unusual Case Report. Indian Journal of Critical Care 0.9 3 46 Medicine, 2019, 23, 276-280. SjĶgren sendromu ve ÅŸiddetli cilt tutulumu mevcut olan katastrofik antifosfolipid sendromu. 0.2 Cukurova Medical Journal, 2020, 45, 746-751. Clinical Features and Management of COVID-19 Associated Hypercoagulability. Cardiac 49 1.7 2 Electrophysiology Clinics, 2021, 14, 41-52. A Case Report of COVID-Associated Catastrophic Antiphospholipid Syndrome Successfully Treated 1.7 with Eculizumab. Journal of Blood Medicine, 2021, Volume 12, 929-933. Catastrophic antiphospholipid syndrome post-Epstein-Barr virus infection: a case report. Hematology, 51 0.2 1 Transfusion and Cell Therapy, 2022, 44, 419-421. Unusual case of antiphospholipid syndrome presenting as adrenal insufficiency. BMJ Case Reports, 2020, 13, e233631. Correspondence on †Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patientsâ€[™] by Trahtemberg et al. Annals of the Rheumatic Diseases, 2021, , 53 0 0.9 annrheumdis-2021-221711. Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities. 4.8 Frontiers in Immunology, 2021, 12, 778913. Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of 56 4.1 7 COVID-19 Coagulopathy. International Journal of Molecular Sciences, 2022, 23, 4946. Anticardiolipin Autoantibodies as Useful Biomarkers for the Prediction of Mortality in Septic 2.2 Patients. Journal of Immunology Research, 2022, 2022, 1-8. Autoantibodies and SARS-CoV-2 infection: A case report. Nauchno-Prakticheskaya Revmatologiya, 2022, 1.0 0 58 60, 271-275. COVID-19 and the antiphospholipid syndrome. Autoimmunity Reviews, 2022, 21, 103206. 5.8 Prevalence and coagulation correlation of anticardiolipin antibodies in patients with COVID-19. 60 1.0 0 Medicine (United States), 2022, 101, e31040. TIMELESS is a key gene mediating thrombogenesis in COVID-19 and antiphospholipid syndrome. Scientific 3.3 Reports, 2022, 12, .

#	Article	IF	CITATIONS
62	A Patient with Severe Fever with Thrombocytopenia Syndrome, Activated Partial Thromboplastin Time Prolongation, and Transient Antiphospholipid Antibodies. Internal Medicine, 2023, , .	0.7	0
63	Microorganisms in the Pathogenesis and Management of Anti-phospholipid Syndrome (Hughes) Tj ETQq1 1 0.784	4314 rgBT	/Qverlock 1
64	From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children. International Journal of Molecular Sciences, 2023, 24, 3001.	4.1	12
65	Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ, The, O, , e069717.	6.0	33
66	Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation. Frontiers in Immunology, 0, 14, .	4.8	1
67	Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis. Biomedicines, 2023, 11, 1241.	3.2	1
68	A study of fibrinolytic system components in donor groups depending on various titers of circulating anti-SARS-CoV-2 IgG in the bloodstream. Blood Coagulation and Fibrinolysis, 2023, 34, 439-445.	1.0	2
69	Anticardiolipin Antibody Determination to Guide Q Fever Treatment. Cureus, 2024, , .	0.5	0
70	Can Antibiotics Cure Autoimmune Diseases?. , 2024, , 407-430.		0
71	What we know and what we don't know about catastrophic antiphospholipid syndrome. Rheumatology, 2024, 63, SI46-SI53.	1.9	1
72	The mystery of autoantibodies solved?. Blood, 2024, 143, 1065-1066.	1.4	0

CITATION REPORT